BioSpace News Archive

Drug spending in the U.S. is projected to grow by 2.5% this year, which will increase overall healthcare spending to $3.3 billion for 2019.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Neos Therapeutics, Inc. announced that Jerry McLaughlin, its Chief Executive Officer, will present a company overview at the upcoming Jefferies 2019 Global Healthcare Conference on Thursday, June 6, 2019 at 2:30 p.m. ET in New York, NY.

Orion Biotechnology Canada Ltd., a developer of novel medical treatments, announced their Chief Medical Officer, Ian McGowan MD Ph.D. FRCP, will be presenting at the ASCO meeting which is being held in Chicago

The company plans to launch its first product in 2020 for the dietary management of Type 2 diabetes.

During the full presentation of the abstract on Friday, Janssen will show that treatment with Erleada significantly improved rPFS with a reduction in the risk of death by 52%. Additionally, in overall survival, the TITAN data showed Erleada and ADT significantly improved OS with a 33% reduction in risk of death.

Retrophin, Inc. announced that Company management will present at the following upcoming investor conferences in June

Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the second milestone has successfully been achieved under Autifony’s agreement with Boehringer Ingelheim

Clinipace, a global full-service contract research organization, has hired four operational, therapeutic, and medical experts to bolster the company’s global strategic development capabilities and medical expertise.

Study is first in the world to evaluate a transcatheter therapy designed to improve left ventricular function for heart failure patients with reduced ejection fraction